Cowen Inc.

Houlihan Lokey Continues Expansion of Its Capital Markets Group With Senior Hire

Retrieved on: 
Monday, April 8, 2024
Finance, Consulting, Banking, Professional Services, Fintech, Private, Houlihan, Cowen Inc., Capital market, Financial services

Houlihan Lokey, Inc. (NYSE:HLI), the global investment bank, announced today that Michael Schwartz has joined as a Managing Director in its Capital Markets Group.

Key Points: 
  • Houlihan Lokey, Inc. (NYSE:HLI), the global investment bank, announced today that Michael Schwartz has joined as a Managing Director in its Capital Markets Group.
  • Prior to Lazard, he was a Managing Director in the Debt Capital Markets group at Cowen and Company.
  • “We are thrilled to be adding an individual of Michael’s caliber to our Capital Markets team,” said Anthony Martino, Managing Director and Global Co-Head of Houlihan Lokey’s Capital Markets Group.
  • Houlihan Lokey’s Capital Markets Group now has more than 90 dedicated finance professionals across offices in New York, Los Angeles, Chicago, Houston, Dallas, San Francisco, London, Manchester, Frankfurt, Milan, Dubai, and Paris.

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Retrieved on: 
Wednesday, March 13, 2024
Research, Takeda Pharmaceutical Company, IO, Biotechnology, PFM, University, Patient, Columbia University, Cowen Inc., Doctor of Philosophy, Biochemistry, New Enterprise Associates, CFA, Cancer, Texas A&M University, Pfizer, Chemical engineering, Drug development, NEA, Therapy, ADC, Pharmaceutical industry

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024.

Key Points: 
  • BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024.
  • “We are thrilled to have Santhosh join the Pyxis Oncology board.
  • Santhosh brings a wealth of business, investment, strategic, and board experience to our team,” said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology.
  • "I am delighted to join the Board of Directors at Pyxis Oncology at such a pivotal moment in the Company's journey as they anticipate data readouts for their lead ADC program, PYX-201, and their IO program, PYX-106, in 2024," said Dr. Santhosh Palani.

Revelation Partners Expands Team and Promotes Internal Talent

Retrieved on: 
Wednesday, March 13, 2024
Growth, Associate, SVB, Ross School of Business, University, Revelation, Marketing, Cowen Inc., Investment, Initial public offering, Multimedia, Amgen, Accounting, Video game

SAUSALITO, Calif., March 11, 2024 /PRNewswire/ -- Revelation Partners announced today it is expanding its team as well as promoting internal talent.

Key Points: 
  • SAUSALITO, Calif., March 11, 2024 /PRNewswire/ -- Revelation Partners announced today it is expanding its team as well as promoting internal talent.
  • "We're excited to add an experienced Associate to the healthcare investment team at Revelation," said Mike Boggs, Managing Partner.
  • In addition to the new hires, Revelation Partners is pleased to highlight the promotion of three team members in 2023.
  • We're always proud to celebrate the growth of internal talent and recognize team members who help us grow the firm and make good investments -- this marks no exception," added Mike Boggs.

Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors

Retrieved on: 
Monday, March 4, 2024
Gene editing, Takeda Pharmaceutical Company, Neoplasm, Investment, Pfizer, Drug discovery, University, CFA, New Enterprise Associates, Proteomics, Doctor of Philosophy, NEA, Therapy, Patient, Radiopharmaceutical, ACRV, Medicine, AP3, Texas A&M University, Chemical engineering, Columbia University, Cowen Inc., Research, PFM, Biochemistry, Pharmaceutical industry

Dr. Palani added, “Acrivon is an entirely science-based company and its AP3 platform is a ground-breaking approach which is broadly applicable across drug discovery and development with significant unrealized potential -- not only in oncology but also in other areas including autoimmune and metabolic disorders, as dysregulated signaling ultimately underlies all diseases. The company currently is focused on oncology with a highly differentiated profile in this space. I am excited to join a distinguished board and support the full realization of the potential of the platform applied to the company’s current pipeline and beyond.”

Key Points: 
  • “Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation precision medicine platform,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • At PFM, Dr. Palani led public and private biotechnology investments, and served on the board of companies in the cell therapy and gene editing fields.
  • Prior to Cowen, Dr. Palani was in oncology drug development at Pfizer Inc. and Takeda Pharmaceuticals.
  • I am excited to join a distinguished board and support the full realization of the potential of the platform applied to the company’s current pipeline and beyond.”

Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments

Retrieved on: 
Thursday, January 25, 2024
Citadel, Portfolio manager, Neoplasm, Pharming, T. Rowe Price, Biology, Research, Health care, SAN, Medical school, Science, Princeton University, University, Pharmacology, Denison University, Cancer, Medication, Biomedical sciences, WEE1, Drug development, Therapy, Ovarian cancer, Doctor of Philosophy, Eventide, Appointment, Cowen Inc.

NEW YORK and SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Diana Hausman, M.D., a member of Zentalis’ Board of Directors, was appointed as Chief Medical Officer, and Kyle Rasbach, Ph.D., Pharm.D., was appointed as Chief Business Officer.

Key Points: 
  • “We are pleased to welcome Diana and Kyle to our management team.
  • During her career, she has contributed to the development of multiple cancer therapeutics, including small molecules, antibody drug conjugates, and immunotherapies.
  • In connection with her appointment as Chief Medical Officer, Dr. Hausman resigned from Zentalis’ Board of Directors.
  • Dr. Brownstein will remain with Zentalis as a consultant for a transitional period.

Cardiovascular Implant Company PECA Labs Names Three New Board Members

Retrieved on: 
Tuesday, July 18, 2023
Health, Medical Devices, Cardiology, Barings Bank, Partnership, University, Raj Rajaratnam, Galleon Group, Anil Kumar, and Rajat Gupta insider trading cases, Wall Street, HUP, Heart, PwC, Yale School of Medicine, Galleon Group, Hospital of the University of Pennsylvania, Publication, Investment, Physician, PECA, UBS, Cowen, Hospital, Medtech, Cowen Inc., Management

The new board members will help guide the company as it develops and commercializes cardiovascular implants based on its novel tunable polymeric material platform.

Key Points: 
  • The new board members will help guide the company as it develops and commercializes cardiovascular implants based on its novel tunable polymeric material platform.
  • Dr. Carpenter is also a serial entrepreneur, including founding Embrella Cardiovascular, which was acquired by Edwards Lifesciences.
  • Jeffery O’Donnell, Sr. brings to PECA Labs more than 25 years of board and chief executive experience at emerging medical device companies.
  • O’Donnell founded and served as CEO for Trice Medical, and before that Embrella Cardiovascular, which was acquired by Edwards Lifesciences.

Coherent Appoints Paul Silverstein as VP, Investor Relations & Corporate Communications

Retrieved on: 
Tuesday, July 11, 2023
Weil, Communication, University, Pryor, Corporate communication, Cornell Law School, Wall Street, MBA, Research, Cowen Inc., Columbia Business School, COHR, Credit Suisse, Weil, Gotshal & Manges, Needham & Company, Institution, Coherent Corp., NYSE, Institutional Investor, Chair, Security (finance)

PITTSBURGH, July 11, 2023 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in materials, networking, and laser technology, today announced that Paul Silverstein has been appointed as Vice President, Investor Relations & Corporate Communications, reporting to Chair and CEO Dr. Vincent D. Mattera, Jr.

Key Points: 
  • PITTSBURGH, July 11, 2023 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in materials, networking, and laser technology, today announced that Paul Silverstein has been appointed as Vice President, Investor Relations & Corporate Communications, reporting to Chair and CEO Dr. Vincent D. Mattera, Jr.
    “The appointment of Paul Silverstein to head up our investor relations and corporate communications teams is the next step in expanding our brand recognition with a renewed focus on investors,” said Dr. Mattera.
  • “Paul will play a pivotal role in representing our company to the investment community.
  • Most recently, he spent the past 10 years as a managing director and senior analyst at Cowen Inc.
  • Prior to his career in equity research, he practiced corporate and securities law as an associate at Pryor Cashman Sherman & Flynn and at Weil, Gotshal & Manges.

William Blair’s Investment in Equities Business Gains Momentum

Retrieved on: 
Monday, April 24, 2023
Banking, Asset Management, Professional Services, Finance, Lazard Capital Markets, Cowen Inc., Alcalde ordinario, University, Lehman Brothers, Private Shared Wireless Network, Southern Methodist University, Stella, Lazard, Methodist University, M.A, Growth, Guggenheim Partners, Economics, Financial services, Security (finance), Truist

William Blair , the premier global boutique with expertise in investment banking, investment management, and private wealth management, announced today the addition of two senior hires in the firm’s equities group.

Key Points: 
  • William Blair , the premier global boutique with expertise in investment banking, investment management, and private wealth management, announced today the addition of two senior hires in the firm’s equities group.
  • “I am thrilled to welcome Paul and Chris to our growing equities team,” said Scott McLaughlin , head of equities at William Blair.
  • “William Blair continues to invest substantially in our equities business, bolstering our global capabilities to deliver unparalleled service and expertise to clients."
  • “I am honored to join William Blair and contribute to the growth of the global equities team,” Ordinario said.

J.F. Lehman & Company Announces New Hires

Retrieved on: 
Monday, April 24, 2023
Kardan University, Senior, Average revenue per user, Internal Revenue Service, Head, New York University School of Law, University School, In-Q-Tel, Millennium Management, LLC, Certified Public Accountant, Investment, U.S. Department of Defense Strategy for Operating in Cyberspace, Comptroller, University, Government, Morgan Stanley, White House, Culture, Cowen Inc., Cravath, Swaine & Moore, Research, Golden Gate Capital, Primary energy, Organization, Partner, Standard Chartered, Paris, Growth, Lafayette College, Airbus, LLP, Cravath, Business, Record, Dartmouth College, Modern Institute of Technology and Management, White, M.B.A, Engineering, Secrecy, Weil, Gotshal & Manges, Intelligence, Marketing, Tuck School of Business, Fore, Security (finance), Nursing, New York University, Finance

Lehman & Company ("JFLCO"), a leading middle-market private equity firm focused exclusively on the aerospace, defense, maritime, government and environmental industries, is pleased to announce several new hires.

Key Points: 
  • Lehman & Company ("JFLCO"), a leading middle-market private equity firm focused exclusively on the aerospace, defense, maritime, government and environmental industries, is pleased to announce several new hires.
  • "The addition of these talented individuals is expected to enhance our transaction sourcing and execution capabilities and other business processes."
  • Mr. Lederman has chaired various creditor committees in large and complex restructurings and served on numerous public and private corporate boards, including currently serving as a director on JFLCO portfolio company, PURIS.
  • A native of New York, Mr. Lederman graduated magna cum laude from New York University, where he earned a B.A.

J.F. Lehman & Company Announces New Hires

Retrieved on: 
Monday, April 24, 2023
Kardan University, Senior, Average revenue per user, Internal Revenue Service, Head, New York University School of Law, University School, In-Q-Tel, Millennium Management, LLC, Certified Public Accountant, Investment, U.S. Department of Defense Strategy for Operating in Cyberspace, Comptroller, University, Government, Morgan Stanley, White House, Culture, Cowen Inc., Cravath, Swaine & Moore, Research, Golden Gate Capital, Primary energy, Organization, Partner, Standard Chartered, Paris, Growth, Lafayette College, Airbus, LLP, Cravath, Business, Record, Dartmouth College, Modern Institute of Technology and Management, White, M.B.A, Engineering, Secrecy, Weil, Gotshal & Manges, Intelligence, Marketing, Tuck School of Business, Fore, Security (finance), Nursing, New York University, Finance

Lehman & Company ("JFLCO"), a leading middle-market private equity firm focused exclusively on the aerospace, defense, maritime, government and environmental industries, is pleased to announce several new hires.

Key Points: 
  • Lehman & Company ("JFLCO"), a leading middle-market private equity firm focused exclusively on the aerospace, defense, maritime, government and environmental industries, is pleased to announce several new hires.
  • "The addition of these talented individuals is expected to enhance our transaction sourcing and execution capabilities and other business processes."
  • Mr. Lederman has chaired various creditor committees in large and complex restructurings and served on numerous public and private corporate boards, including currently serving as a director on JFLCO portfolio company, PURIS.
  • A native of New York, Mr. Lederman graduated magna cum laude from New York University, where he earned a B.A.